Cite
HARVARD Citation
Gettinger, S. et al. (n.d.). Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet oncology. 17 (12), pp. 1683-1696. [Online].